Drugs / INM004
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03388216 | Dec 2017 → Sep 2018 | — | Inmunova S.A. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05569746 | Oct 2022 → May 2023 | Shiga toxin-associated hemolytic uremic syndrome, kidney disorder | Inmunova S.A. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06389474 | Oct 2024 → Aug 2026 overdue | Shiga toxin-associated hemolytic uremic syndrome | Inmunova S.A. | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT04132375 Comparator | Jul 2019 → May 2022 | Shiga toxin-associated hemolytic uremic syndrome, diarrheal disease, kidney disorder | Inmunova S.A. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INM004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03388216 ↗ |
| Action | Inhibit | “Neutralizing equine anti-Stx F(ab')2 antibodies (INM004) have the objective of preventing the development of HUS by blocking the circulating toxins in patients infected with STEC.” NCT04132375 ↗ |
| Modality | Protein / enzyme biologic | “anti-Shiga toxin hyperimmune equine immunoglobulin F(ab')2 fragment (INM004)” NCT03388216 ↗ |
| Route | Intravenous | “Subjects will receive a 1st intravenous dose of 4 mg/kg INM004” NCT04132375 ↗ |